Difference between revisions of "International Federation of Pharmaceutical Manufacturers and Associations"
| Line 20: | Line 20: | ||
From the IFPMA website: | From the IFPMA website: | ||
| + | |||
"The objectives of the Federation, as set out in the Article 2 of the IFPMA Statutes are: | "The objectives of the Federation, as set out in the Article 2 of the IFPMA Statutes are: | ||
* to encourage a global policy environment that is conducive to innovation in medicine, both therapeutic and preventative, for the benefit of patients around the world; | * to encourage a global policy environment that is conducive to innovation in medicine, both therapeutic and preventative, for the benefit of patients around the world; | ||
| Line 25: | Line 26: | ||
* to promote and support the adoption of high standards of manufacturing practices and quality assurance for pharmaceutical products; | * to promote and support the adoption of high standards of manufacturing practices and quality assurance for pharmaceutical products; | ||
* to contribute industry expertise and foster collaborative relationships and partnerships with international organizations, national institutions, governments and non-governmental organizations that are dedicated to the improvement of public health, especially in developing and emerging countries; | * to contribute industry expertise and foster collaborative relationships and partnerships with international organizations, national institutions, governments and non-governmental organizations that are dedicated to the improvement of public health, especially in developing and emerging countries; | ||
| − | * to assure regular contact and experience-sharing and coordinate the efforts of its members towards the realisation of the above objectives. | + | * to assure regular contact and experience-sharing and coordinate the efforts of its members towards the realisation of the above objectives." [http://www.ifpma.org/About_Us/about_mission.aspx] |
Revision as of 17:23, 22 April 2006
The IFPMA describes itself as a "non-profit, non-governmental organization representing industry associations from both developed and developing countries". [1] It is one of the main trade groups lobbying to establish 'public-private partnerships' between the private pharmaceutical industry and public health initiatives. [2]
History and mission
The IFPMA was created in 1968 in order to represent associations of international worldwide research-based pharmaceutical industry and manufacturers of prescribed medicines. The conditions for membership of the Federation include to good manufacturing practices and acceptance of the "IFPMA Code of Pharmaceutical Marketing Practices". In November 2004, the IFPMA decided to make membership available to pharmaceutical companies, as long as these companies fulfil the conditions implied by the Federation’s objectives and mission. [3]
The Federation has established close connections with the United Nations as well as a number of international organisations. Some of them are:
- World Health Organisation (WHO)
- World Trade Organisation (WTO)
- World Intellectual Property Organisation (WIPO)
- United Nations Conference on Trade and Development (UNCTAD)
- United Nations Conference on Trade and Development (UNCTAD)
- Council of Europe
Objectives
From the IFPMA website:
"The objectives of the Federation, as set out in the Article 2 of the IFPMA Statutes are:
- to encourage a global policy environment that is conducive to innovation in medicine, both therapeutic and preventative, for the benefit of patients around the world;
- to promote and support principles of ethical conduct and practices voluntarily agreed upon as exemplified by the IFPMA Code of Pharmaceutical Marketing Practices;
- to promote and support the adoption of high standards of manufacturing practices and quality assurance for pharmaceutical products;
- to contribute industry expertise and foster collaborative relationships and partnerships with international organizations, national institutions, governments and non-governmental organizations that are dedicated to the improvement of public health, especially in developing and emerging countries;
- to assure regular contact and experience-sharing and coordinate the efforts of its members towards the realisation of the above objectives." [5]
Individuals
IFPMA President
- Dr. Daniel Vasella, Chairman and Chief Executive Officer Novartis International AG
IFPMA Vice Presidents
- Dr. Henry A. McKinnell, Jr., Chairman and Chief Executive Officer Pfizer Inc.
- Haruo Naito, President and Chief Executive Officer Eisai Co. Ltd.
Directors
- Dr. Harvey E. Bale, Jr., Director General
- Dr. Odette Morin, Director, Regulatory and Scientific Affairs
- Dr. Eric Noehrenberg, Director, International Trade and Market Policy
- Dr. Ryoko Krause, Director, Biologicals and Vaccines
- Dr. Frédérique Santerre, Health Care Systems (ad-interim)
- Mr. Guy Willis, Director of Communications
- Mr. Takeshi Sano, Japan Liaison Executive
Members
Members are national or regional pharmaceutical industry associations in more than 60 countries and the following “research-based pharmaceutical, biotech, and vaccine companies”:
- Abbott Laboratories
- Akzo Nobel – Organon
- Almirall-Prodesfarma
- AstraZeneca
- Bayer
- Boehringer Ingelheim
- Bristol-Myers Squibb
- Chugai Pharmaceutical
- Eisai
- Eli Lilly
- Esteve
- F-Hoffmann-La Roche
- Astellas Pharma Inc.
- GlaxoSmithKline
- Merck & Co., Inc.
- Menarini S.A.
- Merck KGaA
- Novartis International AG
- Pfizer
- Sanofi-Aventis
- Institut de Recherches Internationales Servier – I.R.I.S.
- Sigma-Tau
- Schering AG
- Schering-Plough
- Takeda
- Wyeth
